Form 10-Q ROCKWELL MEDICAL, INC. For: Sep 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/5/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
Chardan Capital Still Positive on Rockwell Medical (RMTI) Following Q3 Results, Update
November 11, 2014 7:55 AM ESTChardan Capital affirms Rockwell Medical Technologies (Nasdaq: RMTI) at Buy with a price target of $27 following Q3 results.
Analyst Ling Wang noted that RMTI's loss of $0.10 per share was roughly in-line with the firm's $0.11 per share loss estimate.
Wang offered the following commentary:
FDA ODAC panel posted majority vote favoring the approval of Triferic. Last Wednesday, the ODAC panel voted favorably for the approval of RMTI's Triferic... More
